S. Gruden, N Axen and M Hassan
LIDDS AB, Sweden Karolinska Institutet, Sweden
Posters & Accepted Abstracts: Arch Cancer Res
This lecture will address a novel principle to produce slow-release depots containing a water-solvable calcium sulfate formulation encapsulating the anti-androgen substance 2-hydroxyflutamide in a microstructurally designed calcium sulfate matrix. The microstructure of the solidified depot consists of a composite of porous and dense material providing a combination of faster and slower release features. By mixing the drug loaded powder, consisting of densified and non-densified granular components, with an aqueous sodium carboxymethyl cellulose solution, an injectable suspension is formulated, which is injectable and which solidifies in vivo as a result of the ability of calcium sulfate to solidify by hydration. This technology has been tested in four clinical trials with injection into the prostate gland in order to decrease the prostate volume and to delay the prostate cancer progression. In addition to these subjects, attendees of this lecture will be familiarized with the future promising potential therapy areas for intra-tumoral injection which are close to enter clinical trial evaluation in cancer patients.
E-mail:
stefan.gruden@liddspharma.com stefan.gruden@ki.se
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 